AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12394686 — intervention group
Group type: COMPARATOR
Intervention: Control (resection alone or resection plus another treatment)
Number of subjects: 4863
Study 12394686 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (BCG) with maintenance treatment
Number of subjects: 4863
Study 9813759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 57
Study 9813759 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 8132849 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen tablets (250 mg)
Number of subjects: 23
Study 8132849 — intervention group
Group type: COMPARATOR
Intervention: Naproxen suspension (250 mg)
Number of subjects: 23
Study 8132849 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen tablets and suspension
Number of subjects: 23
Study 2628331 — intervention group
Group type: EXPERIMENTAL
Intervention: Staples
Number of subjects: 100
Study 2628331 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 100
Study 788749 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxprenolol (80 mg)
Number of subjects: 6
Study 788749 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release oxprenolol (160 mg)
Number of subjects: 6
Study 31881340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative lumbar drainage (LD)
Number of subjects: 189
Study 30429032 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 or 10 mg/kg Q3W plus carboplatin AUC 6 mg/mL/min plus paclitaxel 200 mg/m2 (cohort A)
Number of subjects: 74
Study 30429032 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6 mg/mL/min plus paclitaxel 200 mg/m2 plus bevacizumab 15 mg/kg (cohort B)
Number of subjects: 74
Study 30429032 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 mg/mL/min plus pemetrexed 500 mg/m2 (cohort C)
Number of subjects: 74
Study 27440535 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional grape juice (400 mL)
Number of subjects: 24
Study 27440535 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic grape juice (400 mL)
Number of subjects: 24
Study 27440535 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 24
Study 24432999 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/d sitagliptin with insulin therapy (group A)
Number of subjects: 30
Study 24432999 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy without sitagliptin (group B)
Number of subjects: 30
Study 22918176 — intervention group
Group type: EXPERIMENTAL
Intervention: Rank‐Ordered Calories
Number of subjects: 0
Study 22918176 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored Calories
Number of subjects: 0
Study 22918176 — intervention group
Group type: COMPARATOR
Intervention: Calories
Number of subjects: 0
Study 22918176 — intervention group
Group type: COMPARATOR
Intervention: No Calories
Number of subjects: 0
Study 20934756 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider tonsillotomy (MIT)
Number of subjects: 501
Study 20934756 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery tonsillectomy (ECT)
Number of subjects: 501
Study 18661005 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin for 7 days
Number of subjects: 120
Study 18661005 — intervention group
Group type: COMPARATOR
Intervention: Analgesic alone
Number of subjects: 120
Study 15955034 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent-onset TM (</=1 year)
Number of subjects: 117
Study 15955034 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-duration TM (>1 year)
Number of subjects: 117
Study 15955034 — intervention group
Group type: EXPERIMENTAL
Intervention: TM with medication overuse (recent onset)
Number of subjects: 117
Study 15955034 — intervention group
Group type: EXPERIMENTAL
Intervention: TM without medication overuse (recent onset)
Number of subjects: 117
Study 15955034 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent onset of chronic daily headache (CDH)
Number of subjects: 117
Study 15955034 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent onset of migraine (<36 months)
Number of subjects: 117
Study 15955034 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger ages (</=15 years)
Number of subjects: 117
Study 12892193 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 112
Study 12892193 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 112
Study 12892193 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (XRT)
Number of subjects: 112
Study 10879896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention including computerized or manual cancer screening reminders, continuing medical education seminars, Vietnamese-language health education materials, newsletters, and oncology data-query programs
Number of subjects: 20
Study 10879896 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract)
Number of subjects: 20
Study 8970830 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 12
Study 1279290 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1-16 mg) once daily for 16 weeks
Number of subjects: 15
Study 1279290 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 15
Study 3905414 — intervention group
Group type: COMPARATOR
Intervention: BTS 49 465 (200 mg oral dose)
Number of subjects: 0
Study 3905414 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 31060545 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated chronic disease clinic care for hypertension
Number of subjects: 4554
Study 31060545 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit frequency determined by drug supply chain rather than clinical indication
Number of subjects: 4554
Study 29622029 — intervention group
Group type: EXPERIMENTAL
Intervention: GP model of hospital-at-home care
Number of subjects: 131
Study 29622029 — intervention group
Group type: COMPARATOR
Intervention: Hospital specialist model of hospital-at-home care
Number of subjects: 131
Study 26662208 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose rituximab (375 mg/m² weekly)
Number of subjects: 31
Study 26662208 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose rituximab (20 mg/m² 3x week)
Number of subjects: 31
Study 26662208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination mAb therapy (alemtuzumab with either standard or low dose rituximab)
Number of subjects: 31
Study 23899405 — intervention group
Group type: EXPERIMENTAL
Intervention: MYLO
Number of subjects: 48
Study 23899405 — intervention group
Group type: COMPARATOR
Intervention: ELIZA
Number of subjects: 48
Study 22400810 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT) 1 gram/20 mg daily, increased to 2 tablets daily after 4 weeks
Number of subjects: 796
Study 22400810 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT)
Number of subjects: 796
Study 20170751 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weekly 1-hour sessions of CBT
Number of subjects: 71
Study 20170751 — intervention group
Group type: EXPERIMENTAL
Intervention: four 1-hour CBT sessions over 10 weeks
Number of subjects: 71
Study 20170751 — intervention group
Group type: COMPARATOR
Intervention: wait list control
Number of subjects: 71
Study 18594925 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted total gastrectomy (LATG)
Number of subjects: 38
Study 18594925 — intervention group
Group type: COMPARATOR
Intervention: Conventional open total gastrectomy (OTG)
Number of subjects: 38
Study 16002819 — intervention group
Group type: EXPERIMENTAL
Intervention: High-saturated fatty acid (SFA) diet
Number of subjects: 59
Study 16002819 — intervention group
Group type: COMPARATOR
Intervention: Low-fat and high-carbohydrate diet (CHO diet)
Number of subjects: 59
Study 16002819 — intervention group
Group type: COMPARATOR
Intervention: High-monounsaturated fatty acid (MUFA) diet (Mediterranean diet)
Number of subjects: 59
Study 16002819 — intervention group
Group type: COMPARATOR
Intervention: SFA diet
Number of subjects: 59
Study 12486652 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump for cardiopulmonary bypass (n = 54)
Number of subjects: 103
Study 12486652 — intervention group
Group type: COMPARATOR
Intervention: Roller pump for cardiopulmonary bypass (n = 49)
Number of subjects: 103
Study 10509772 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (LCT)
Number of subjects: 18
Study 10509772 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT)
Number of subjects: 18
Study 10509772 — intervention group
Group type: COMPARATOR
Intervention: Control group (benign gastrointestinal diseases)
Number of subjects: 18
Study 8610948 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim‐sulfamethoxazole
Number of subjects: 181
Study 8610948 — intervention group
Group type: EXPERIMENTAL
Intervention: clindamycin‐primaquine
Number of subjects: 181
Study 8610948 — intervention group
Group type: EXPERIMENTAL
Intervention: dapsone‐trimethoprim
Number of subjects: 181
Study 8610948 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 181
Study 1750635 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural infusion of bupivacaine (Group B, n = 12)
Number of subjects: 26
Study 1750635 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of pethidine (Group P, n = 14)
Number of subjects: 26
Study 1750635 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural infusion of bupivacaine (Group B)
Number of subjects: 26
Study 1750635 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of pethidine (Group P)
Number of subjects: 26
Study 7199923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 12-2503
Number of subjects: 6
Study 7199923 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 6
Study 7199923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30194380 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (25 mg per day for 1 week, then 50 mg per day up to 12 months)
Number of subjects: 0
Study 30194380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30194380 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 0
Study 27761987 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous/Moderate exercise
Number of subjects: 220
Study 27761987 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 220
Study 27761987 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 220
Study 25591756 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (MDZ) at a dose of 10 μmol/L in OGD+MDZ group
Number of subjects: 0
Study 25591756 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (MDZ) at a dose of 10 μmol/L and IL‐6 at a dose of 50 ng/mL in OGD+MDZ+IL‐6 group
Number of subjects: 0
Study 25591756 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 25591756 — intervention group
Group type: COMPARATOR
Intervention: Oxygen glucose deprivation (OGD) group
Number of subjects: 0
Study 24307262 — intervention group
Group type: EXPERIMENTAL
Intervention: Na(18)F PET/CT imaging at 45, 90, and 180 minutes after Na(18)F administration
Number of subjects: 38
Study 24307262 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Na(18)F PET/CT imaging
Number of subjects: 38
Study 22566743 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (TPAD‐IC)
Number of subjects: 16
Study 22566743 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (CPAD‐IC)
Number of subjects: 16
Study 19164456 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus gemcitabine (docetaxel 60 mg/m² on day 1 and day 8, gemcitabine 800 mg/m² on days 1 and 8, every 21 days)
Number of subjects: 130
Study 19164456 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone (docetaxel 60 mg/m² on day 1)
Number of subjects: 130
Study 19164456 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus gemcitabine
Number of subjects: 130
Study 19164456 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 130
Study 17444309 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring (n=25)
Number of subjects: 50
Study 17444309 — intervention group
Group type: COMPARATOR
Intervention: Standard sedation management (n=25)
Number of subjects: 50
Study 15871587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternocleidomastoid muscle flap reconstruction
Number of subjects: 24
Study 15871587 — intervention group
Group type: COMPARATOR
Intervention: No flap reconstruction (Control)
Number of subjects: 24
Study 15871587 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 12450060 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (intermittent cyclical)
Number of subjects: 48
Study 12450060 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (3 d/week)
Number of subjects: 48
Study 12450060 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-exercising controls)
Number of subjects: 48
Study 9522199 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (telephone and first interview)
Number of subjects: 109
Study 9522199 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone‐alone intervention
Number of subjects: 109
Study 9522199 — intervention group
Group type: COMPARATOR
Intervention: Usual intake procedure
Number of subjects: 109
Study 10577572 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril 400 mg/day
Number of subjects: 47
Study 10577572 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg/day
Number of subjects: 47
Study 10577572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 1802923 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital radiotherapy combined with systemic glucocorticoids (Group 1)
Number of subjects: 30
Study 1802923 — intervention group
Group type: COMPARATOR
Intervention: Orbital radiotherapy alone (Group 2)
Number of subjects: 30
Study 6402051 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% amino acid infusion
Number of subjects: 20
Study 6402051 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (D5W) infusion
Number of subjects: 20
Study 30985391 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy
Number of subjects: 1591
Study 30985391 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1591
Study 29218707 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin administered with food
Number of subjects: 179
Study 29218707 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin administered in a fasting state
Number of subjects: 179
Study 26765479 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing regimen (group A)
Number of subjects: 70
Study 26765479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic model-based dosing scheme (group B)
Number of subjects: 70
Study 23392267 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment model (intervention group)
Number of subjects: 184
Study 23392267 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (treatment-as-usual control group)
Number of subjects: 184
Study 23392267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 184
Study 22337471 — intervention group
Group type: EXPERIMENTAL
Intervention: GRT9906 (120-240 mg)
Number of subjects: 117
Study 22337471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 22337471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (200-400 mg)
Number of subjects: 117
Study 22337471 — intervention group
Group type: EXPERIMENTAL
Intervention: GRT9906
Number of subjects: 117
Study 22337471 — intervention group
Group type: EXPERIMENTAL
Intervention: GRT9906 and Tramadol
Number of subjects: 117
Study 19682845 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% polygeline
Number of subjects: 30
Study 19682845 — intervention group
Group type: COMPARATOR
Intervention: 6% hydroxyethyl starch
Number of subjects: 30
Study 17947505 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 min/day of treadmill exercise while supine in 53 mmHg LBNP, followed by 5 min of resting LBNP
Number of subjects: 30
Study 17947505 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 15984517 — intervention group
Group type: EXPERIMENTAL
Intervention: WHF arm (study group), 1000 mg/m2 of 5-FU administered over the course of 5 hr once a week by hepatic arterial infusion
Number of subjects: 91
Study 15984517 — intervention group
Group type: COMPARATOR
Intervention: CVI arm (control group), 300 mg/m2 of 5-FU administered as a continuous intravenous infusion daily for 5 days followed by 2 days' rest
Number of subjects: 91
Study 12018753 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based and family-based intervention
Number of subjects: 4776
Study 12018753 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention only
Number of subjects: 4776
Study 12018753 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4776
Study 9256127 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating schedule of chemotherapy and irradiation (CDE chemotherapy split into four courses of five daily fractions delivered on days 14 to 21 of the second and subsequent chemotherapy courses)
Number of subjects: 335
Study 9256127 — intervention group
Group type: COMPARATOR
Intervention: Sequential schedule of chemotherapy and irradiation (five courses of CDE chemotherapy followed by thoracic irradiation 50 Gy in 20 daily fractions)
Number of subjects: 335
Study 8289038 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (30 U given intravenously) at home
Number of subjects: 311
Study 8289038 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (both treatment groups)
Number of subjects: 311
Study 8289038 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who died
Number of subjects: 311
Study 8289038 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 311
Study 8289038 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors with infarction
Number of subjects: 311
Study 8289038 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors without infarction
Number of subjects: 311
Study 8289038 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with infarction with Q-waves
Number of subjects: 311
Study 8289038 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with infarction without Q-waves
Number of subjects: 311
Study 8289038 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic treatment at home
Number of subjects: 311
Study 3560788 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine (3 X 40 mg for 2 weeks)
Number of subjects: 10
Study 3560788 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (2 X 40 mg for 2 weeks)
Number of subjects: 10
Study 3560788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30209286 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo 'analgesic' pills
Number of subjects: 0
Study 30209286 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological traits
Number of subjects: 0
Study 27616217 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered brief intervention (up to five home sessions focusing on physical activity and healthy eating)
Number of subjects: 320
Study 27616217 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered brief intervention
Number of subjects: 320
Study 27616217 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (CVD risk assessment and one-time consultation)
Number of subjects: 320
Study 23906510 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed match‐to‐sample secondary task involving photographs of positive emotional valence
Number of subjects: 0
Study 23906510 — intervention group
Group type: COMPARATOR
Intervention: Delayed match‐to‐sample secondary task involving photographs of negative emotional valence
Number of subjects: 0
Study 23906510 — intervention group
Group type: COMPARATOR
Intervention: Delayed match‐to‐sample secondary task involving photographs of neutral emotional valence
Number of subjects: 0
Study 23906510 — intervention group
Group type: COMPARATOR
Intervention: No secondary task
Number of subjects: 0
Study 22716928 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean nutrition bar (80 kcal)
Number of subjects: 0
Study 22716928 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean nutrition bar (592 kcal)
Number of subjects: 0
Study 22716928 — intervention group
Group type: COMPARATOR
Intervention: Test cookie (80 kcal)
Number of subjects: 0
Study 22716928 — intervention group
Group type: COMPARATOR
Intervention: Test cookie (592 kcal)
Number of subjects: 0
Study 22716928 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean nutrition bar and Test cookie
Number of subjects: 0
Study 21330816 — intervention group
Group type: EXPERIMENTAL
Intervention: CD group (trained on the patient simulator performing general anesthesia for emergency CD)
Number of subjects: 32
Study 21330816 — intervention group
Group type: COMPARATOR
Intervention: SHAM group (trained on the simulator using a different general anesthetic scenario unrelated to obstetric anesthesia)
Number of subjects: 32
Study 21330816 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 19074082 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusions
Number of subjects: 0
Study 19074082 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic platelet transfusions
Number of subjects: 0
Study 16422806 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 229
Study 16422806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 12875474 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise (PE) program supervised by a physiotherapist
Number of subjects: 18
Study 12875474 — intervention group
Group type: COMPARATOR
Intervention: Recommended exercise (oral and written instructions)
Number of subjects: 18